HC Wainwright Lifts Earnings Estimates for Gain Therapeutics

Gain Therapeutics, Inc. (NASDAQ:GANX) – Equities researchers at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for shares of Gain Therapeutics in a report released on Monday, November 25th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.95) per share for the year, up from their previous forecast of ($1.06). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2024 earnings at ($0.18) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.68) EPS.

Several other research analysts also recently weighed in on GANX. Chardan Capital reiterated a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a report on Friday, August 9th. Oppenheimer reiterated an “outperform” rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Wednesday, August 14th.

Gain Therapeutics Trading Up 0.6 %

Shares of GANX opened at $1.74 on Wednesday. The stock has a fifty day moving average of $2.08 and a two-hundred day moving average of $1.71. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The company has a market capitalization of $46.14 million, a PE ratio of -1.58 and a beta of 0.33. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $5.33.

Institutional Trading of Gain Therapeutics

Several institutional investors have recently made changes to their positions in GANX. Hohimer Wealth Management LLC purchased a new stake in shares of Gain Therapeutics during the 2nd quarter valued at $422,000. Warberg Asset Management LLC purchased a new stake in shares of Gain Therapeutics during the 2nd quarter valued at $66,000. Renaissance Technologies LLC grew its stake in shares of Gain Therapeutics by 154.2% during the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after buying an additional 72,000 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares during the period. 11.97% of the stock is owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.